Clinical Trials Browser

Phase 1 × OTHER × AZD 6244 × Clear all

NCT06502171 2026-03-12

NF113

Phase 1 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03326310 2025-12-29

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT03162627 2025-10-14

Selumetinib and Olaparib in Solid Tumors

Phase 1 Active not recruiting

Breast Neoplasms

NCT02768766 2023-08-31

Intermittent Selumetinib for Uveal Melanoma

Phase 1 Completed

Uveal Melanoma, Melanoma

NCT01160926 2023-04-24

DREAMtherapy

Phase 1 Terminated

Gastrointestinal

Rectal Neoplasms

NCT02503358 2023-03-21

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT01146756 2023-02-15

MEKRT

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01586624 2021-10-07

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

Phase 1 Completed

61 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01242605 2016-05-13

ABC-04

Phase 1 Completed

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma